Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy

Phase 2

GGuangdong Provincial People's Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Locally Advanced Rectal Cancer (LARC)Active, not recruiting

Locally Advanced Rectal Cancer (LARC)Phase 2

Active, not recruiting

Timeline

Expected Milestones

Q1 2030

Phase 2Active, not recruiting

Locally Advanced Rectal Cancer (LARC)

NCT06933251

Clinical

Trials by Indication[1]

Locally Advanced Rectal Cancer (LARC)1 trial

Clinical Study of PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy in the Treatment of pMMR/MSS Locally Advanced Rectal Cancer

Active, not recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06933251·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Guangdong Provincial People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: GGuangdong Provincial People's Hospital

Related News